


**Supplemental Figure 1. FL3 and FL37 increase cell viability and increase protein expression of known flavagline ligands PHB and PHB2 in IEC-6 cells.** (A) Cell viability using LDH assay of cells treated with FL3 or FL37 for 16 hr. n = 8 per treatment. **P* < 0.05 vs. vehicle. (B) Polarized IEC-6 cells were treated with 10 nM FL3 or FL37 for increasing time. Representative western blots are shown for PHB, PHB2, phospho-p38, total p38 and β-tubulin (loading control).




**Supplemental Figure 2. FL3 and FL37 do not induce Stat3, SAPK/JNK, ERK, or AKT activation in Caco2-BBE cells.** Cells were treated with 10 nM FL3 (A) or FL37 (B) for increasing time. Representative western blots are shown.







**Supplemental Figure 3. Pretreatment with FL3 or FL37 decreases TNFα- induced expression of NFκB p65 and Cox2 and enhances IEC-6 cell viability during TNFα or IFNγ treatment.** (A) Cells were pretreated with increasing concentrations of FL3 or FL37 for 1 hour, followed by treatment with 10 ng/ml TNFα or 50 ng/ml IFNγ for 16 hr. Total protein was isolated for western blotting for expression of NFκB p65, Cox2, and β-actin (loading control). (B) Cells were pretreated with 10 nM FL3 or FL37 for 1 hour followed by treatment with 10 ng/ml TNFα or 50 ng/ml IFNγ for 16 hr. Cell viability was measured using the LDH assay. $^{*}P < 0.05$ vs. vehicle. $^{\#}P < 0.05$ vs. TNFα + vehicle; $^{\dagger}P < 0.05$ vs. IFNγ + vehicle. n = 8 per treatment.




**Supplemental Figure 4. In vivo administration of FL3 does not induce Stat3, SAPK/JNK, ERK, or AKT activation in the colon during DSS colitis.** Representative western blots of total protein isolated from whole colon on day 6 of DSS colitis.